IMRX (Immuneering Corp) Earnings per share for the last four quarters

Public company logo of Immuneering Corp (IMRX)

Current price action for Immuneering Corporation (IMRX), which focuses on developing targeted anti-tumor agents, demonstrates the significance of 42.70. Geopolitical fragmentation hinders global testing and the procurement of biomaterials, complicating logistics. Meanwhile, business success relies on the precision of drug delivery and the pursuit of investment. Current capital allows the company to conduct research without the risk of funding shortages by systematically utilizing its reserves.

IMRX immuneering.com Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Immuneering Corp - analytical breakdowns and key metrics (IMRX)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Immuneering (IMRX)
Signature product of Immuneering

A defensive portfolio is constructed through rigorous screening of profit dynamics, where the rate of change in earnings per share over the last twelve months plays a key role. This metric measures the annual growth of EPS, allowing for an assessment of the business's fundamental stability between quarterly reports. For Immuneering Corporation (IMRX), which integrates IT specialists and oncologists, this indicator reflects the efficiency of investments in drug development. By analyzing the rolling annual EPS change on GURU.Markets, an investor can see the actual speed of innovation capitalization.

Competitor analysis for Immuneering Corporation

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX